+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Temozolomide Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • July 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5393427
Temozolomide is a second-generation alkylating agent. It is an oral chemotherapeutic drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. By 2020, Temozolomide has been included in China's Class B medical insurance. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.





According to the market research, the sales value of Temozolomide in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.

The analyst expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, as the incidence of primary brain cancer increases, other cancers can cause secondary brain cancer. Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to increase. At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal fluid barrier and mild adverse reactions. The analyst predicts that the sales value and sales volume of Temozolomide in the Chinese market will have room for increase from 2021 to 2025.

Topics Covered:

  • The impact of COVID-19 on China's Temozolomide market
  • Sales value of China's Temozolomide 2016-2020
  • Competitive landscape of China's Temozolomide market
  • Prices of Temozolomide in China
  • Prices of Temozolomide in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Temozolomide market
  • Prospect of China's Temozolomide market from 2021 to 2025
Frequently Asked Questions about the Chinese Temozolomide Market

What is the estimated value of the Chinese Temozolomide Market?

The Chinese Temozolomide Market was estimated to be valued at CNY 560.57 Million in 2016.

What is the growth rate of the Chinese Temozolomide Market?

The growth rate of the Chinese Temozolomide Market is 10.6%, with an estimated value of CNY 1396.8 Million by 2025.

What is the forecasted size of the Chinese Temozolomide Market?

The Chinese Temozolomide Market is estimated to be worth CNY 1396.8 Million by 2025.

Who are the key companies in the Chinese Temozolomide Market?

Key companies in the Chinese Temozolomide Market include Merck Sharp & Dohme Ltd (TEMODAL), Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing), Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning), Schering and Jiangsu Hengrui Medicine Company Ltd..

Table of Contents

1 Relevant Concepts of Temozolomide
1.1 Indications for Temozolomide
1.2 Development of Temozolomide in China
1.3 Governmental Approval of Temozolomide in China
1.4 The Impact of COVID-19 on Temozolomide sales in China
2 Sales of Temozolomide in China, 2016-2020
2.1 Sales Value of Temozolomide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Temozolomide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Temozolomide by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Temozolomide Manufacturers in China in 2020
3.1 Analysis of Market Share of Major Temozolomide Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Merck Sharp & Dohme Ltd
3.2.1 Enterprise Profile
3.2.2 Sales of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China
3.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Diqing (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.’s Temozolomide) in China
3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd.’s Temozolomide) in China
3.5 Schering-Plough Canada
3.5.1 Enterprise Profile
3.5.2 Sales of TEMODAL (Schering-Plough Canada’s Temozolomide) in China
3.6 Jiangsu Hengrui Medicine Company Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China
4 Prices of Temozolomide for Different Manufacturers in China, 2020-2021
4.1 Merck Sharp & Dohme Ltd (TEMODAL)
4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
4.3 Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
4.4 Schering-Plough Canada (TEMODAL)
4.5 Jiangsu Hengrui Medicine Company Ltd.
5 Prospect of Chinese Temozolomide drug Market, 2021-2025
5.1 Influential Factors of Chinese Temozolomide Market Development
5.1.1 The Impact of COVID-19 on Chinese Temozolomide Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Temozolomide Injection Registration in China
Chart Sales Value of Temozolomide Injection over the World
Chart Sales Value of Temozolomide Injection in China, 2016-2020
Chart Sales Value of Temozolomide Injection in China by Region, 2016-2020
Chart Sales Volume of Temozolomide Injection in China, 2016-2020
Chart Sales Volume of Temozolomide Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Temozolomide Manufacturers in China, 2016-2020
Chart Sales Value and Volume of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China, 2016-2020
Chart Sales Value and Volume of Diqing in China, 2016-2020
Chart Sales Value and Volume of Jiaoning in China, 2016-2020
Chart Sales Value and Volume of TEMODAL (Schering-Plough Canada’s Temozolomide) in China, 2016-2020
Chart Sales Value and Volume of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China, 2016-2020
Chart Referential Prices of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China, 2020-2021
Chart Referential Prices of Diqing in China, 2020-2021
Chart Referential Prices of Jiaoning in China, 2020-2021
Chart Referential Prices of TEMODAL (Schering-Plough Canada’s Temozolomide) in China, 2020-2021
Chart Referential Prices of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China, 2020-2021
Chart Forecast on Sales Value of Temozolomide in China, 2021-2025
Chart Forecast on Sales Volume of Temozolomide in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Merck Sharp & Dohme Ltd (TEMODAL)
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
  • Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
  • Schering-Plough Canada (TEMODAL)
  • Jiangsu Hengrui Medicine Company Ltd.

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...